Humanized BCMA antibody and BCMA-CAR-T cells

Abstract

The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising V H having the amino acid sequence of SEQ ID NO: 3 and V L having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

What is claimed is: 
     
       1. A chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus:
 (i) a single-chain variable fragment (scFv) comprising V H  having the amino acid sequence of SEQ ID NO: 3 and V L  having the amino acid sequence of SEQ ID NO: 5, 
 (ii) a transmembrane domain, 
 (iii) at least one co-stimulatory domain, and 
 (iv) an intracellular activating domain that transmits a signal to cause activation of a biological process in a cell; 
 wherein the CAR has the amino acid sequence of SEQ ID NO: 17 or 20.